Dogwood Therapeutics, Inc.
No SEC Form 4 filings for $DWTX in the last 30 days.
See all $DWTX insider activity →Dogwood Therapeutics (DWTX) completed enrollment in its Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain, with 239 patients. Topline results are due in November 2026. Halneuron, a non-opioid analgesic, has FDA Fast Track designation. DWTX stock is currently trading at $1.87.
Modular Medical (MODD) rose 13.48% in overnight trading after a 23.37% drop earlier, planning a 2026 launch for its Pivot tubeless patch pump. Jin Medical (ZJYL) gained 20.79% with no specific news. InnovAge (INNV) increased 9.51% after reporting a 15.9% revenue rise. Pyxis Oncology (PYXS) climbed 5% ahead of a key clinical update. Pulse Biosciences (PLSE) fell 2.48% despite clinical trial progress. Dermata (DRMA) rose 7.20% after launching its Tome skincare brand. Dogwood Therapeutics (DWTX) ga
Dogwood Therapeutics (DWTX) reported interim results from its Phase 2b trial of Halneuron for neuropathic pain, showing trends toward separation from placebo. The company plans to expand the trial to 210-240 patients for 80% statistical power. Dogwood is also developing synthetic tetrodotoxin for future studies and aims to begin Phase 3 trials in 2025, with a potential new drug application submission in 2029.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning DWTX (Dogwood Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent DWTX coverage spans financial news, technology and earnings.
Enrollment completion reduces execution risk and sets up a November data catalyst.
Trial progress may attract speculative interest ahead of fall readout.
Positive interim data may lift the stock ahead of the Phase 2b readout and future FDA engagement.
Trial enrollment progress and cash runway reduce near‑term execution risk, supporting upside.
Near-term catalyst is the fall 2026 topline readout for Halneuron Phase 2b, supported by new trial expansion and cash runway guidance.
AlphAI scores every news story that mentions DWTX with an AI model for sentiment and relevance, and aggregates insider trades from Dogwood Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Dogwood Therapeutics (DWTX) completed enrollment in its Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain, with 239 patients. Topline results are due in November 2026. Halneuron, a non-opioid analgesic, has FDA Fast Track designation. DWTX stock is currently trading at $1.87.
2 min readModular Medical (MODD) rose 13.48% in overnight trading after a 23.37% drop earlier, planning a 2026 launch for its Pivot tubeless patch pump. Jin Medical (ZJYL) gained 20.79% with no specific news. InnovAge (INNV) increased 9.51% after reporting a 15.9% revenue rise. Pyxis Oncology (PYXS) climbed 5% ahead of a key clinical update. Pulse Biosciences (PLSE) fell 2.48% despite clinical trial progress. Dermata (DRMA) rose 7.20% after launching its Tome skincare brand. Dogwood Therapeutics (DWTX) ga
3 min readDogwood Therapeutics (DWTX) reported interim results from its Phase 2b trial of Halneuron for neuropathic pain, showing trends toward separation from placebo. The company plans to expand the trial to 210-240 patients for 80% statistical power. Dogwood is also developing synthetic tetrodotoxin for future studies and aims to begin Phase 3 trials in 2025, with a potential new drug application submission in 2029.
2 min readAethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.
3 min readDogwood Therapeutics, Inc. (DWTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled – - Commencement of Phase 2b Long-Term Extension Study to assess H
6 min readDogwood Therapeutics, Inc. (DWTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. DOGWOOD THERAPEUTICS, INC._June 16, 2026 0001818844 false --12-31 0001818844 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Da
3 min readATLANTA, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Dogwood Therapeutics, Inc. DWTX ( the "Company" ) , a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will participate in the H.C. Wainwright 27th Annual Global ...
3 min readATLANTA, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Dogwood Therapeutics, Inc. ( Nasdaq: DWTX ) ( the "Company" ) , a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will participate in the H.C.
2 min readATLANTA, June 03, 2025 ( GLOBE NEWSWIRE ) -- Dogwood Therapeutics, Inc. ( Nasdaq: DWTX ) ( "Dogwood" or the "Company" ) , a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced that CEO, Greg Duncan, will present a ...
2 min readATLANTA, June 03, 2025 ( GLOBE NEWSWIRE ) -- Dogwood Therapeutics, Inc.
2 min read
